Table 2.
Patient Characteristic at Start of Pazopanib Treatment
| Start of Pazopanib n (%) | |
|---|---|
| Age | |
| Median (range) | 39(18–62) |
| Site of Metastasis | |
| Lung | 1(5) |
| Extra pulmonary | 2(11) |
| Lung and extra pulmonary | 11(58) |
| Local | 5(26) |
| Time from Diagnosis | |
| Median in year (range) | 2.67(0.8–38) |
| Treatment Before Pazopanib∗ | |
| Median number of lines | 2(0–6) |
| Median number of cycles† | 10.5(4–20) |
| Pazopanib Start Dose | |
| 800 mg | 15(79) |
| 600 mg | 1(5) |
| 400 mg | 3(16) |
| Best Response to Pazopanib | |
| Partial response | 6(32) |
| Stable disease | 7(37) |
| Progression | 4(21) |
| Not evaluable | 2(11) |
∗
Treatment given for metastatic disease.
†
For patient who were treated with chemotherapy before pazopanib.